Shots:
- Formycon and Klinge Biopharma have signed a semi-exclusive licensing deal with Horus Pharma to commercialize the FYB203/Baiama (Biosimilar, Eylea) in selected EC, following a similar agreement with Teva in Jan for covering major parts of the EU & Israel
- Klinge will receive upfront, milestone payments, and royalties on net sales, with Formycon earning a share (mid-single to low-double-digit %) of all payments. Formycon will also manage the FYB203 supply chain and receive service fees and volume-based profit for commercial supply
- Aflibercept treats neovascular age-related macular degeneration (nAMD) and other serious retinal diseases, a leading cause of blindness in people over 60 in EU and North America
Ref: Formycon | Image: Klinge Biopharma and Formycon | Press Release
Related News:- Valorum Biologics and Formycon Collaborate to Commercialize FYB203 (Biosimilar, Eylea) Across US and Canada
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
